What is Regis Technologies?
Regis Technologies specializes in the process and analytical development of small molecule APIs, serving pharmaceutical companies with a comprehensive suite of services. Their offerings include cGMP manufacturing, analytical development, and custom API solutions. Complementing their development services, Regis also provides essential chromatography consumables, such as HPLC and SFC columns, alongside specialty and imaging reagents. The company's commitment to precision and deep expertise enables clients to effectively navigate the intricate journey of molecule development, from initial discovery through to final delivery.
How much funding has Regis Technologies raised?
Regis Technologies has raised a total of $3M across 2 funding rounds:
Debt
$1M
Debt
$2M
Debt (2020): $1M with participation from PPP
Debt (2021): $2M led by PPP
Key Investors in Regis Technologies
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Regis Technologies?
The enterprise-level funding and recent strategic investment indicate Regis Technologies is poised for significant expansion and further innovation. This capital infusion is likely to fuel advancements in their API development capabilities, enhance their manufacturing capacity, and potentially broaden their portfolio of chromatography products. The company's focus on supporting pharmaceutical clients through complex development cycles suggests a strategic direction aimed at solidifying its role as a critical partner in bringing new therapeutics to market.
See full Regis Technologies company page
